MedTrace Logo

Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium

NCT03554343 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136339

Last updated 2021-03-10

No results posted yet for this study

Summary

Medico-economic study of Newborn screening of Spinal Muscular Atrophy

Conditions

Interventions

DIAGNOSTIC_TEST

test for SMN1 exon 7 deletion

Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers

Sponsors & Collaborators

  • AveXis, Inc.

    collaborator INDUSTRY

  • Biogen

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • Association Belge contre les Maladies neuro Musculaires

    collaborator UNKNOWN

  • Centre Hospitalier Régional de la Citadelle

    lead OTHER

Principal Investigators

  • Laurent Servais, MD, PhD · CRMN

Eligibility

Max Age
7 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-05
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554343 on ClinicalTrials.gov